AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company’s mission is to use its expertise, dedicated people, and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries.
In Switzerland, AbbVie has around 150 employees. The Swiss subsidiary AbbVie is headquartered in Baar in the canton of Zug. Composed of twelve members from a variety of backgrounds, this team raises synergies between expertise and know-how in various fields.
Contact
AbbVie AG
Neuhofstrasse 23
CH – 6341 Baar
Switzerland
Telephone: + 41 41 399 15 00
Michele Ravara brings a global perspective and deep strategic experience to his role as general manager of AbbVie Switzerland, following nearly a decade leading the Oncology Business from a global…
AbbVie Switzerland’s Jon Helsdingen outlines how he has led the Swiss affiliate through a full scale office move, the acquisition and integration of Allergan and the COVID-19 pandemic in a…
Olaf Weppner, General Manager of AbbVie Switzerland, highlights AbbVie’s intended foray into oncology, the importance of immunology to the group, the challenges and opportunities of the Swiss market and his…
Ophthalmology is a booming niche, with investment flowing in, M&A up, and a burgeoning cast of biotechs – including the three European leaders profiled below – vying for a share…
Natural remedies are on the rise. The USD 80 billion global natural health products market is projected to nearly double by 2033, according to Market Growth Reports, as patients with…
Ophthalmology is one of the hottest niches in pharma right now. Investment is flowing in, M&A is up, and a broad cast of actors – from Big Pharma to legacy…
One in six infections worldwide is now resistant to first-line antibiotics, making antimicrobial resistance (AMR) a major global health threat. Despite an extremely challenging commercial landscape, a handful of bold…
Switzerland has become a global leader in cutting-edge cancer research, with close collaborations between research institutions, hospitals, and private industry fostering the next generation of globally impactful cancer innovation. …
As global trade tensions escalate, Switzerland’s export-driven pharmaceutical industry finds itself at a challenging moment. In May 2025, the United States imposed tariffs of up to 39 percent on Swiss…
In an uncertain world, Europe – with Switzerland at its heart – is reclaiming its role as an epicentre for testing, scaling, and integrating new medical technologies. While much…
Manufacturing – long sidelined as a relatively prosaic element of the global pharma supply chain – is back in the news. Investment in manufacturing facilities is skyrocketing as sponsors rush…
Switzerland stands among the world’s leading pharmaceutical manufacturing and export hubs; though that position now faces headwinds from recent US policy moves, as detailed elsewhere in this report. Yet making…
With the Trump administration imposing tariffs of up to 39 percent on Swiss goods (recently reduced to 15 percent), the pressure on Switzerland’s most influential industrial sector – pharmaceuticals –…
For a tiny Alpine nation nestled deep in the interior of continental Europe, Switzerland boasts a spectacularly vibrant biotech scene. This is because “the country manages to leverage its compact…
Helsinn has recently entered one of the most consequential transformations in its history. As it prepares for a new transition at the helm of the company, Executive Chairman Riccardo Braglia…
See our Cookie Privacy Policy Here
